blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3094352

EP3094352 - COMPOSITIONS AND METHODS FOR TREATMENT AND DETECTION OF CANCERS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  30.07.2021
Database last updated on 14.09.2024
FormerThe patent has been granted
Status updated on  21.08.2020
FormerGrant of patent is intended
Status updated on  23.04.2020
FormerExamination is in progress
Status updated on  12.10.2018
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024 [2024/41]
Applicant(s)For all designated states
Academia Sinica
128, Sec. 2
Academia Sinica Road
Nan-Kang
Taipei 115 / TW
[2016/47]
Inventor(s)01 / WONG, Chi-Huey
P.O. Box 8154
Rancho Santa Fe, California 92067 / US
02 / LOU, Yi-Wei
2F.
No. 1 Ln. 92 Xinmin Street
Nangang District
Taipei City 115 / TW
03 / LIN, Chih-Wei
12F.
No. 179-3 Maijin Road
Anle District
Keelung City 204 / TW
04 / YEH, Shih-Chi
c/o Academia Sinica
128 Academia Road
Section 2
Nankang
Taipei 115 / TW
05 / HSU, Tsui-Ling
No. 266 DongShih Stret
Xi-Zhi District
New Taipei City 221 / TW
06 / WU, Chung-Yi
No. 78-1
Dongshi Street
Xi-Zhi District
New Taipei City 221 / TW
07 / WU, Han-Chung
12F.-1
No. 10
Lane 43
Sanmin Road, Songshan District
Taipei City 105 / TW
 [2016/47]
Representative(s)Lavoix
Bayerstraße 83
80335 München / DE
[N/P]
Former [2016/47]Lavoix
Bayerstrasse 83
80335 München / DE
Application number, filing date15737180.816.01.2015
[2016/47]
WO2015US11748
Priority number, dateUS201461928132P16.01.2014         Original published format: US 201461928132 P
[2016/47]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2015109180
Date:23.07.2015
Language:EN
[2015/29]
Type: A2 Application without search report 
No.:EP3094352
Date:23.11.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 23.07.2015 takes the place of the publication of the European patent application.
[2016/47]
Type: B1 Patent specification 
No.:EP3094352
Date:23.09.2020
Language:EN
[2020/39]
Search report(s)International search report - published on:US15.10.2015
(Supplementary) European search report - dispatched on:EP07.11.2017
ClassificationIPC:C07K16/18, C07K16/30, A61K39/395, A61P35/00, G01N33/574, C12N5/095
[2017/36]
CPC:
C07K16/18 (EP,KR,US); A61K39/3955 (KR); A61P35/00 (EP);
A61P43/00 (EP); C07K16/3053 (EP,KR,US); G01N33/57407 (EP,KR,US);
G01N33/57492 (KR,US); A61K2039/505 (EP,KR,US); C07K2317/21 (EP,US);
C07K2317/24 (EP,US); C07K2317/33 (EP,US); C07K2317/54 (US);
C07K2317/55 (US); C07K2317/565 (KR,US); C07K2317/567 (KR);
C07K2317/622 (EP,KR,US); C07K2317/734 (EP,KR,US); C07K2317/92 (EP,US);
G01N2800/52 (EP,KR,US) (-)
Former IPC [2016/47]A61K39/395, G01N33/574
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/47]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG UND ZUM NACHWEIS VON KREBS[2016/47]
English:COMPOSITIONS AND METHODS FOR TREATMENT AND DETECTION OF CANCERS[2016/47]
French:COMPOSITIONS ET MÉTHODES POUR TRAITER ET DÉTECTER DES CANCERS[2016/47]
Entry into regional phase09.08.2016National basic fee paid 
09.08.2016Search fee paid 
09.08.2016Designation fee(s) paid 
09.08.2016Examination fee paid 
Examination procedure09.08.2016Examination requested  [2016/47]
17.05.2018Amendment by applicant (claims and/or description)
16.10.2018Despatch of a communication from the examining division (Time limit: M06)
15.04.2019Reply to a communication from the examining division
06.08.2019Despatch of a communication from the examining division (Time limit: M04)
26.11.2019Reply to a communication from the examining division
24.04.2020Communication of intention to grant the patent
11.08.2020Fee for grant paid
11.08.2020Fee for publishing/printing paid
11.08.2020Receipt of the translation of the claim(s)
Opposition(s)24.06.2021No opposition filed within time limit [2021/35]
Fees paidRenewal fee
30.01.2017Renewal fee patent year 03
26.01.2018Renewal fee patent year 04
31.01.2019Renewal fee patent year 05
30.01.2020Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU16.01.2015
AL23.09.2020
AT23.09.2020
CY23.09.2020
CZ23.09.2020
DK23.09.2020
EE23.09.2020
ES23.09.2020
FI23.09.2020
HR23.09.2020
IT23.09.2020
LT23.09.2020
LV23.09.2020
MC23.09.2020
MK23.09.2020
MT23.09.2020
NL23.09.2020
PL23.09.2020
RO23.09.2020
RS23.09.2020
SE23.09.2020
SI23.09.2020
SK23.09.2020
SM23.09.2020
TR23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
IE16.01.2021
LU16.01.2021
IS23.01.2021
PT25.01.2021
BE31.01.2021
[2024/41]
Former [2024/29]HU16.01.2015
AL23.09.2020
AT23.09.2020
CY23.09.2020
CZ23.09.2020
DK23.09.2020
EE23.09.2020
ES23.09.2020
FI23.09.2020
HR23.09.2020
IT23.09.2020
LT23.09.2020
LV23.09.2020
MC23.09.2020
MK23.09.2020
NL23.09.2020
PL23.09.2020
RO23.09.2020
RS23.09.2020
SE23.09.2020
SI23.09.2020
SK23.09.2020
SM23.09.2020
TR23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
IE16.01.2021
LU16.01.2021
IS23.01.2021
PT25.01.2021
BE31.01.2021
Former [2024/22]HU16.01.2015
AL23.09.2020
AT23.09.2020
CY23.09.2020
CZ23.09.2020
DK23.09.2020
EE23.09.2020
ES23.09.2020
FI23.09.2020
HR23.09.2020
IT23.09.2020
LT23.09.2020
LV23.09.2020
MC23.09.2020
MK23.09.2020
NL23.09.2020
PL23.09.2020
RO23.09.2020
RS23.09.2020
SE23.09.2020
SI23.09.2020
SK23.09.2020
SM23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
IE16.01.2021
LU16.01.2021
IS23.01.2021
PT25.01.2021
BE31.01.2021
Former [2023/30]HU16.01.2015
AL23.09.2020
AT23.09.2020
CY23.09.2020
CZ23.09.2020
DK23.09.2020
EE23.09.2020
ES23.09.2020
FI23.09.2020
HR23.09.2020
IT23.09.2020
LT23.09.2020
LV23.09.2020
MC23.09.2020
NL23.09.2020
PL23.09.2020
RO23.09.2020
RS23.09.2020
SE23.09.2020
SI23.09.2020
SK23.09.2020
SM23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
IE16.01.2021
LU16.01.2021
IS23.01.2021
PT25.01.2021
BE31.01.2021
Former [2023/27]HU16.01.2015
AL23.09.2020
AT23.09.2020
CZ23.09.2020
DK23.09.2020
EE23.09.2020
ES23.09.2020
FI23.09.2020
HR23.09.2020
IT23.09.2020
LT23.09.2020
LV23.09.2020
MC23.09.2020
NL23.09.2020
PL23.09.2020
RO23.09.2020
RS23.09.2020
SE23.09.2020
SI23.09.2020
SK23.09.2020
SM23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
IE16.01.2021
LU16.01.2021
IS23.01.2021
PT25.01.2021
BE31.01.2021
Former [2022/34]AL23.09.2020
AT23.09.2020
CZ23.09.2020
DK23.09.2020
EE23.09.2020
ES23.09.2020
FI23.09.2020
HR23.09.2020
IT23.09.2020
LT23.09.2020
LV23.09.2020
MC23.09.2020
NL23.09.2020
PL23.09.2020
RO23.09.2020
RS23.09.2020
SE23.09.2020
SI23.09.2020
SK23.09.2020
SM23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
IE16.01.2021
LU16.01.2021
IS23.01.2021
PT25.01.2021
BE31.01.2021
Former [2022/07]AL23.09.2020
AT23.09.2020
CZ23.09.2020
DK23.09.2020
EE23.09.2020
ES23.09.2020
FI23.09.2020
HR23.09.2020
IT23.09.2020
LT23.09.2020
LV23.09.2020
MC23.09.2020
NL23.09.2020
PL23.09.2020
RO23.09.2020
RS23.09.2020
SE23.09.2020
SI23.09.2020
SK23.09.2020
SM23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
IE16.01.2021
LU16.01.2021
IS23.01.2021
PT25.01.2021
Former [2021/48]AL23.09.2020
AT23.09.2020
CZ23.09.2020
DK23.09.2020
EE23.09.2020
ES23.09.2020
FI23.09.2020
HR23.09.2020
IT23.09.2020
LT23.09.2020
LV23.09.2020
MC23.09.2020
NL23.09.2020
PL23.09.2020
RO23.09.2020
RS23.09.2020
SE23.09.2020
SI23.09.2020
SK23.09.2020
SM23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
LU16.01.2021
IS23.01.2021
PT25.01.2021
Former [2021/43]AL23.09.2020
AT23.09.2020
CZ23.09.2020
DK23.09.2020
EE23.09.2020
ES23.09.2020
FI23.09.2020
HR23.09.2020
LT23.09.2020
LV23.09.2020
MC23.09.2020
NL23.09.2020
PL23.09.2020
RO23.09.2020
RS23.09.2020
SE23.09.2020
SI23.09.2020
SK23.09.2020
SM23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
LU16.01.2021
IS23.01.2021
PT25.01.2021
Former [2021/40]AL23.09.2020
AT23.09.2020
CZ23.09.2020
DK23.09.2020
EE23.09.2020
ES23.09.2020
FI23.09.2020
HR23.09.2020
LT23.09.2020
LV23.09.2020
MC23.09.2020
NL23.09.2020
PL23.09.2020
RO23.09.2020
RS23.09.2020
SE23.09.2020
SI23.09.2020
SK23.09.2020
SM23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
IS23.01.2021
PT25.01.2021
Former [2021/37]AL23.09.2020
AT23.09.2020
CZ23.09.2020
DK23.09.2020
EE23.09.2020
ES23.09.2020
FI23.09.2020
HR23.09.2020
LT23.09.2020
LV23.09.2020
NL23.09.2020
PL23.09.2020
RO23.09.2020
RS23.09.2020
SE23.09.2020
SI23.09.2020
SK23.09.2020
SM23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
IS23.01.2021
PT25.01.2021
Former [2021/36]AL23.09.2020
AT23.09.2020
CZ23.09.2020
EE23.09.2020
ES23.09.2020
FI23.09.2020
HR23.09.2020
LT23.09.2020
LV23.09.2020
NL23.09.2020
PL23.09.2020
RO23.09.2020
RS23.09.2020
SE23.09.2020
SI23.09.2020
SK23.09.2020
SM23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
IS23.01.2021
PT25.01.2021
Former [2021/28]AL23.09.2020
AT23.09.2020
CZ23.09.2020
EE23.09.2020
ES23.09.2020
FI23.09.2020
HR23.09.2020
LT23.09.2020
LV23.09.2020
NL23.09.2020
PL23.09.2020
RO23.09.2020
RS23.09.2020
SE23.09.2020
SK23.09.2020
SM23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
IS23.01.2021
PT25.01.2021
Former [2021/25]AL23.09.2020
AT23.09.2020
CZ23.09.2020
EE23.09.2020
ES23.09.2020
FI23.09.2020
HR23.09.2020
LT23.09.2020
LV23.09.2020
NL23.09.2020
PL23.09.2020
RO23.09.2020
RS23.09.2020
SE23.09.2020
SM23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
IS23.01.2021
PT25.01.2021
Former [2021/23]AT23.09.2020
CZ23.09.2020
EE23.09.2020
FI23.09.2020
HR23.09.2020
LT23.09.2020
LV23.09.2020
NL23.09.2020
RO23.09.2020
RS23.09.2020
SE23.09.2020
SM23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
PT25.01.2021
Former [2021/22]CZ23.09.2020
EE23.09.2020
FI23.09.2020
HR23.09.2020
LT23.09.2020
LV23.09.2020
NL23.09.2020
RO23.09.2020
RS23.09.2020
SE23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
PT25.01.2021
Former [2021/21]FI23.09.2020
HR23.09.2020
LT23.09.2020
LV23.09.2020
NL23.09.2020
RS23.09.2020
SE23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
PT25.01.2021
Former [2021/20]FI23.09.2020
HR23.09.2020
LT23.09.2020
LV23.09.2020
NL23.09.2020
RS23.09.2020
SE23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
Former [2021/18]FI23.09.2020
HR23.09.2020
LV23.09.2020
NL23.09.2020
RS23.09.2020
SE23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
Former [2021/10]FI23.09.2020
HR23.09.2020
LV23.09.2020
RS23.09.2020
SE23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
Former [2021/09]FI23.09.2020
SE23.09.2020
BG23.12.2020
NO23.12.2020
GR24.12.2020
Former [2021/08]FI23.09.2020
SE23.09.2020
BG23.12.2020
NO23.12.2020
Former [2021/07]FI23.09.2020
NO23.12.2020
Documents cited:Search[IDY]  - KANNAGI R ET AL, "Stage-specific embryonic antigens (SSEA-3 and -4) are epitopes of a unique globo-series ganglioside isolated from human teratocarcinoma cells", EMBO JOUR, OXFORD UNIVERSITY PRESS, SURREY, GB, (19830101), vol. 2, ISSN 0261-4189, pages 2355 - 2361, XP008102258 [ID] 1-3,6-8,12-14,35-37 * whole document, especially the Abstract; Table II * [Y] 15-22
 [IY]  - Y.-J. LIANG ET AL, "Switching of the core structures of glycosphingolipids from globo- and lacto- to ganglio-series upon human embryonic stem cell differentiation", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, US, (20101213), vol. 107, no. 52, doi:10.1073/pnas.1007290108, ISSN 0027-8424, pages 22564 - 22569, XP055394006 [I] 1-3,6-8,12-14,35-37 * whole document, especially the abstract; paragraph bridging the columns of page 22564 * [Y] 15-22

DOI:   http://dx.doi.org/10.1073/pnas.1007290108
 [IY]  - KATAGIRI Y U ET AL, "Laminin binding protein, 34/67 laminin receptor, carries stage-specific embryonic antigen-4 epitope defined by monoclonal antibody Raft.2", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 332, no. 4, doi:10.1016/J.BBRC.2005.05.052, ISSN 0006-291X, (20050715), pages 1004 - 1011, (20050608), XP027218738 [I] 1-3,6-8,12-14,35-37 * whole document, especially the Abstract; page 1005, left-hand column, lines 3-9 * [Y] 15-22

DOI:   http://dx.doi.org/10.1016/j.bbrc.2005.05.052
 [IDY]  - Y.-L. HUANG ET AL, "Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, US, (20130125), vol. 110, no. 7, doi:10.1073/pnas.1222649110, ISSN 0027-8424, pages 2517 - 2522, XP055394157 [ID] 1-3,6-8,12-14,35-37 * whole document, especially the Abstract; Figures 5, 7; Supplementary Figure S2; sentence bridging pages 2520-2521 and following paragraph * [Y] 15-22

DOI:   http://dx.doi.org/10.1073/pnas.1222649110
 [T]  - Anonymous, "Anti-Stage-Specific Embryonic Antigen-4 Antibody, clone MC-813-70 | MAB4304", (2017), URL: https://www.merckmillipore.com/NL/en/product/Anti-Stage-Specific-Embryonic-Antigen-4-Antibody,-clone-MC-813-70,MM_NF-MAB4304, (20170726), XP055394107 [T] 1-3,6-8,12-22,35-37 * the whole document *
International search[XY]WO2006064983  (KOREA RES INST OF BIOSCIENCE [KR], et al) [X] 1, 3, 4 * entire document * [Y] 39;
 [A]WO2008087260  (SUOMEN PUNAINEN RISTI VERIPALV [FI], et al) [A] 1, 3, 4, 13, 14, 26-37, 39 * entire document *;
 [Y]US2009123439  (YUN KYUSON [US], et al) [Y] 31-35 * entire document *;
 [Y]US2012328646  (WONG CHI-HUEY [TW], et al) [Y] 34 * entire document *;
 [XY]WO2013130603  (UNIV TEXAS [US]) [X] 26-30 * entire document * [Y] 36;
 [Y]WO2013152034  (MERRIMACK PHARMACEUTICALS INC [US]) [Y] 39 * entire document *;
 [XY]  - MARCATO et al., "Chapter 17: The Rocky Road from Cancer Stem Cell Discovery to Diagnostic Applicability", Cancer Stem Cells Theories and Practice, (20110322), pages 335 - 360, URL: http://www.intechopen.com/download/pdf/14473, XP055231292 [X] 37 * . entire document * [Y] 31-36

DOI:   http://dx.doi.org/10.5772/13923
 [PX]  - LOU et al., "Stage Specific Embryonic Antigen-4 as a Potential Therapeutic Target in Glioblastoma Multiforme and other Cancers", Proceedings of the National Academy of Sciences, (20140218), vol. 111, no. 7, pages 2482 - 2487, XP055218264 [PX] 1, 3, 4, 13, 14, 26-37, 39 * . entire document *

DOI:   http://dx.doi.org/10.1073/pnas.1400283111
by applicantUS3773919
 EP0003089
 USRE30985E
 US4419446
 US4560655
 US4601978
 WO8700195
 US4657866
 US4676980
 US4767704
 US4816567
 WO9003430
 US4927762
 US4965199
 US4975278
 EP0404097
 WO9100360
 US5004697
 WO9110741
 US5061620
 WO9200373
 US5112596
 WO9209690
 US5122469
 WO9301161
 WO9306213
 WO9308829
 WO9316185
 US5264365
 US5268164
 WO9404690
 WO9411026
 WO9607754
 US5506206
 US5508192
 US5545807
 US5545806
 US5565332
 US5569825
 WO9634096
 WO9633735
 US5571894
 US5580717
 US5587458
 US5625126
 US5633425
 US5639635
 US5641870
 US5648237
 US5661016
 US5686416
 US5733743
 WO9824893
 US5840523
 US5869046
 US6004940
 US6027888
 US6083715
 US6265150
 US6329173
 US2002025313
 US2002038086
 US2002065259
 US2003073713
 US2003083299
 US2003104402
 US2003129186
 US2003162695
 WO03077945
 EP1391213
 US6703019
 US2004131692
 US2004204354
 US2005089473
 US2005124533
    - WARD et al., Nature, (19890000), vol. 341, pages 544 - 546
    - ABRAHMSEN et al., EMBO J., (19850000), vol. I; II, page 3901
    - CHOTHIA et al., J. Mol. Biol., (19870000), vol. 196, pages 901 - 917
    - JONES et al., Nature, (19860000), vol. I-IV, pages 522 - 525
    - RIECHMANN et al., Nature, (19880000), vol. 154; 155, pages 323 - 327
    - CHEN, Y. et al., J. Mol Biol, (19990000), vol. 293, pages 865 - 881
    - PRESTA et al., Cancer Res., (19970000), vol. 57, pages 4593 - 4599
    - CLACKSON et al., Nature, (19910000), vol. 352, pages 624 - 628
    - KOHLER et al., Nature, (19750000), vol. 256, page 495
    - HAMMERLING et al., Monoclonal Antibodies and T-Cell hybridomas, Elsevier, (19810000), vol. 73, pages 563 - 681
    - TOMLINSON et al., J. Mol. Biol., (19920000), vol. 226, pages 889 - 896
    - SIDHU et al., J. Mol. Biol., (20040000), vol. 340, no. 5, pages 1073 - 1093
    - FELLOUSE, Proc. Natl. Acad. Sci. USA, (20040000), vol. 101, no. 34, pages 12467 - 12472
    - LEE et al., J. Immunol. Methods, (20040000), vol. 284, no. 1-2, pages 119 - 132
    - JAKOBOVITS et al., Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, pages 7889 - 7893
    - JAKOBOVITS et al., Nature, (19930000), vol. 362, pages 255 - 258
    - BRUGGEMANN et al., Year in Immunol., (19930000), vol. 7, page 33
    - MARKS et al., Bio. Technology, (19920000), vol. 10, pages 779 - 783
    - LONBERG et al., Nature, (19940000), vol. 368, pages 812 - 813
    - FISHWILD et al., Nature Biotechnol., (19960000), vol. 14, pages 826 - 851
    - LONBERGHUSZAR, Intern. Rev. Immunol., (19950000), vol. 13, pages 65 - 93
    - MORRISON et al., Proc. Natl. Acad. Sci. USA, (19840000), vol. 81, pages 6851 - 6855
    - PRESTA, Curr. Op. Struct. Biol., (19920000), vol. 2, pages 593 - 596
    - VASWANIHAMILTON, Ann. Allergy, Asthma & Immunol., (19980000), vol. 1, pages 105 - 115
    - HARRIS, Biochem. Soc. Transactions, (19950000), vol. 23, pages 1035 - 1038
    - HURLEGROSS, Curr. Op. Biotech., (19940000), vol. 5, pages 428 - 433
    - HOOGENBOOM et al., J. Mol. Biol., (19910000), vol. 222, pages 581 - 597
    - BARBAS et al., Proc Nat. Acad. Sci. USA, (19940000), vol. 113, pages 3809 - 3813
    - CARTER et al., Bio/Technology, (19920000), vol. 10, pages 163 - 167
    - ; SCHIER et al., Gene, (19950000), vol. 159, pages 203 - 155
    - JACKSON et al., J. Immunol., (19950000), vol. 154, no. 7, pages 3310 - 2004
    - HAWKINS et al., J. Mol. Biol., vol. 226, pages 889 - 896
    - AGNEW, Chem. Intl. Ed. Engl., (19940000), vol. 33, pages 183 - 186
    - VERHOEYEN et al., Science, (19880000), vol. 239, pages 1534 - 1536
    - KOZBOR, J. Immunol., (19840000), vol. 133, page 3001
    - BRODEUR et al., Monoclonal Antibody Production Techniques and Applications, American Society for Microbiology, (19870000), vol. 2, pages 1190 - 1219
    - GUSS et al., EMBO J., (19860000), vol. 5, pages 15671575 - 103
    - BARNES et al., Anal. Biochem., (19800000), vol. 102, page 255
    - MCCAFFERTY et al., Nature, (19900000), vol. 348, pages 552 - 554
    - SKERRA et al., Curr. Opinion in Immunol., (19930000), vol. 5, pages 256 - 262
    - PLUCKTHUN, Immunol. Rev., (19920000), vol. 130, pages 151 - 188
    - MORRISON et al., Proc. Nat. Acad. Sci., (19840000), vol. 81, page 6851
    - NEUBERGER et al., Nature, (19840000), vol. 314, page 452
    - PRESTA et al., J. Immunol., (19930000), vol. 151, page 2623
    - CARTER et al., Proc. Natl. Acad Sci. USA, (19920000), vol. 89, page 4285
    - PRESTA et al., J. Immnol., (19930000), vol. 151, page 2623
    - BRUGGERMANN et al., Year in Immuno., (19930000), vol. 7, page 33
    - WINTER et al., Annu. Rev. Immunol., (19940000), vol. 12, pages 433 - 455
    - MCCAFFERTY et al., Nature, (19820000), vol. 297, pages 598 - 601
    - MARKS et al., J. Mol Biol., (19910000), vol. 222, pages 581 - 597
    - WATERHOUSE et al., Nuc. Acids. Res., (19930000), vol. 21, pages 2265 - 2266
    - FREDMAN PHOIST HCOLLINS VPGRANHOLM LVENNERHOLM L, "Sialyllactotetraosylceramide, a ganglioside marker for human malignant gliomas", J Neurochem, (19880000), vol. 50, no. 3, pages 912 - 919
    - HARA et al., Microbial Drug Resistance, (19960000), vol. 2, pages 63 - 72
    - CHEN et al., J Bio Chem, (19990000), vol. 274, pages 19601 - 19605
    - HOOGENBOOM et al., Nucl. Acids Res., (19910000), vol. 1-3, pages 4133 - 4137
    - WINTER et al., Ann. Rev. Immunol., (19940000), vol. 12, pages 433 - 455
    - GRIFFITHS et al., EMBO J, (19930000), vol. 12, pages 725 - 734
    - ORLANDI et al., Proc. Natl. Acad. Sci. (USA, (19890000), vol. 86, pages 5728 - 5732
    - JONES et al., Biotechnol., (19910000), vol. 9, pages 88 - 89
    - ORUM et al., Nucleic Acids Res., (19930000), vol. 21, pages 4491 - 4498
    - MATSUDA et al., Nature Genet., (19930000), vol. 3, pages 88 - 94
    - CARTER et al., Proc. Natl. Acad. Sci. USA, (19920000), vol. 89, pages 4285 - 3580
    - WILLIAMSWINTER, Eur. J. Immunol., (19930000), vol. 23, pages 1456 - 1461
    - HOGREFE et al., Gene, (19930000), vol. 128, pages 119 - 126
    - WATERHOUSE et al., Nucl. Acids Res., (19930000), vol. 21, pages 2265 - 2266
    - BARBAS et al., Proc. Natl. Acad. Sci. USA, (19910000), vol. 88, pages 7978 - 7982
    - EMBLETON et al., Nucl. Acids Res., (19920000), vol. 20, pages 3831 - 3837
    - BASS et al., Proteins, (19900000), vol. 8, pages 309 - 314
    - MARKS et al., Biotechnol., (19920000), vol. 10, pages 779 - 783
    - PLUCKTHUN, Immunol. Revs, (19920000), vol. 130, page 151
    - LEUNG et al., Technique, (19890000), vol. 1, pages 11 - 15
    - ENGELS et al., Agnew. Chem., (19890000), vol. 28, pages 716 - 734
    - Methods in Enzymology, (19760000), vol. 44
    - SIEBENLIST et al., Cell, (19800000), vol. 20, page 269
    - YANSURA et al., METHODS: A Companion to Methods in Enzymol., (19920000), vol. 4, pages 151 - 158
    - SIMMONS et al., J. Immunol. Methods, (20020000), vol. 263, pages 133 - 147
    - BOTHMANNPLUCKTHUN, J. Biol. Chem., (20000000), vol. 275, pages 17106 - 17113
    - ARIE et al., Mol. Microbiol., (20010000), vol. 39, pages 199 - 210
    - LINDMARK et al., J. Immunol. Meth., (19830000), vol. 62, pages 1 - 13
    - GRAHAM et al., J. Gen Virol., (19770000), vol. 36, page 59
    - URLAUB et al., Proc. Natl. Acad. Sci. USA, (19800000), vol. 77, page 4216
    - TM4, Mather, Biol. Reprod., (19800000), vol. 23, pages 243 - 251
    - MATHER et al., Annals N.Y. Acad. Sci., (19820000), vol. 383, pages 44 - 68
    - HAM et al., Meth. Enz., (19790000), vol. 58, page 44
    - MORIMOTO et al., Journal of Biochemical and Biophysical Methods, (19920000), vol. 24, pages 107 - 117
    - BRENNAN et al., Science, (19850000), vol. 229, page 81
    - BOERNER et al., J. Immunol., (19910000), vol. 147, page 60
    - BRUGGERMANN et al., Year in Immunol, (19930000), vol. 7, page 33
    - MILSTEINCUELLO, Nature, (19830000), vol. 305, page 537
    - TRAUNECKER et al., EMBO J., (19910000), vol. 10, page 3655
    - SURESH et al., Methods in Enzymology, (19860000), vol. 121, page 210
    - SHALABY et al., J. Exp. Med., (19920000), vol. 175, pages 217 - 225
    - KOSTELNY et al., J. Immunol., (19920000), vol. 148, no. 5, pages 1547 - 1553
    - GRUBER et al., J. Immunol., (19940000), vol. 152, page 5368
    - CUNNINGHAMWELLS, Science, (19890000), vol. 244, pages 1081 - 1085
    - A. L. LEHNINGE, Biochemistry, Worth Publishers, (19750000), pages 73 - 75
    - SYRIGOSEPENETOS, Anticancer Research, (19990000), vol. 19, pages 605 - 614
    - NICULESCU-DUVAZSPRINGER, Adv. Drg Del. Rev., (19970000), vol. 26, pages 151 - 172
    - BALDWIN et al., Lancet, (19860315), pages 603 - 05
    - THORPE et al., "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", Monoclonal Antibodies '84: Biological And Clinical Applications, (19850000), vol. 84, pages 475 - 506
    - ROWLAND et al., Cancer Immunol. Immunother., (19860000), vol. 21, pages 183 - 87
    - MANDLER et al., Jour. of the Nat. Cancer Inst., (20000000), vol. 92, no. 19, pages 1573 - 1581
    - MANDLER et al., Bioorganic & Med. Chem. Letters, (20000000), vol. 10, pages 1025 - 1028
    - MANDLER et al., Bioconjugate Chem., (20020000), vol. 13, pages 786 - 791
    - LIU et al., Proc. Natl. Acad. Sci. USA, (19960000), vol. 93, pages 8618 - 8623
    - LODE et al., Cancer Res., (19980000), vol. 58, page 2928
    - HINMAN et al., Cancer Res., (19930000), vol. 53, pages 3336 - 3342
    - KAM et al., Proc. Natl. Acad. Sci., (20050000), vol. 102, pages 11600 - 11605
    - TRAYLOR TDHOGAN EL, "Gangliosides of human cerebral astrocytomas", JNeurochem, (19800000), vol. 34, no. 1, pages 126 - 131
    - MARASCO, Gene Therapy, (19970000), vol. 4, pages 11 - 15
    - KONTERMANN, Methods, (20040000), vol. 34, pages 163 - 170
    - CHEN et al., Proc. Natl. Acad. Sci. USA, (19990000), vol. 96, pages 4325 - 4329
    - PAPANASTASSIOU et al., Gene Therapy, (20020000), vol. 9, pages 398 - 406
    - BOBO et al., Proc. Natl. Acad. Sci. USA, (19940000), vol. 91, pages 2076 - 2080
    - GILL et al., Nature Med., (20030000), vol. 9, pages 589 - 595
    - SVENNERHOLM L et al., "Human brain gangliosides: developmental changes from early fetal stage to advanced age", Biochim Biophys Acta, (19890000), vol. 1005, no. 2, doi:10.1016/0005-2760(89)90175-6, pages 109 - 117, XP023577891

DOI:   http://dx.doi.org/10.1016/0005-2760(89)90175-6
    - eptide and Protein Drug Delivery, Marcel Dekker, Inc., (19910000), pages 247 - 301
    - JONES, A., Adv. Drug Delivery Rev., (19930000), vol. 10, pages 29 - 90
    - LOUIS DN et al., "The 2007 WHO classification of tumours of the central nervous system", Acta Neuropathol, (20070000), vol. 114, no. 2, doi:10.1007/s00401-007-0243-4, pages 97 - 109, XP055450017

DOI:   http://dx.doi.org/10.1007/s00401-007-0243-4
    - VAN MEIR EG et al., "Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma", CA Cancer J Clin, (20100000), vol. 60, no. 3, pages 166 - 193
    - MEYER MA, "Malignant gliomas in adults", N Engl J Med, (20080000), vol. 359, no. 17, page 1850
    - MEEZAN EWU HCBLACK PHROBBINS PW, "Comparative studies on the carbohydrate-containing membrane components of normal and virus-transformed mouse fibroblasts. II. Separation of glycoproteins and glycopeptides by sephadex chromatography", Biochemistry, (19690000), vol. 8, no. 6, pages 2518 - 2524
    - HAKOMORI S, "Glycosylation defining cancer malignancy: new wine in an old bottle", Proc Natl Acad Sci USA, (20020000), vol. 99, no. 16, pages 10231 - 10233
    - LAU KSDENNIS JW, "N-Glycans in cancer progression", Glycobiology, (20080000), vol. 18, no. 10, pages 750 - 760
    - VAN BEEK WPSMETS LAEMMELOT P, "Increased sialic acid density in surface glycoprotein of transformed and malignant cells--a general phenomenon?", Cancer Res, (19730000), vol. 33, no. 11, pages 2913 - 2922
    - SELL S, "Cancer-associated carbohydrates identified by monoclonal antibodies", Hum Pathol, (19900000), vol. 21, no. 10, doi:10.1016/0046-8177(90)90250-9, pages 1003 - 1019, XP026242978

DOI:   http://dx.doi.org/10.1016/0046-8177(90)90250-9
    - HAKOMORI SZHANG Y, "Glycosphingolipid antigens and cancer therapy", Chem Biol, (19970000), vol. 4, no. 2, doi:10.1016/S1074-5521(97)90253-2, pages 97 - 104, XP009010432

DOI:   http://dx.doi.org/10.1016/S1074-5521(97)90253-2
    - TAYLOR-PAPADIMITRIOU JEPENETOS AA, "Exploiting altered glycosylation patterns in cancer: progress and challenges in diagnosis and therapy", Trends Biotechnol, (19940000), vol. 12, no. 6, doi:10.1016/0167-7799(94)90121-X, pages 227 - 233, XP023595355

DOI:   http://dx.doi.org/10.1016/0167-7799(94)90121-X
    - BIRKLE SZENG GGAO LYU RKAUBRY J, "Role of tumor-associated gangliosides in cancer progression", Biochimie, (20030000), vol. 85, no. 3-4, pages 455 - 463
    - FREDMAN P et al., "Potential ganglioside antigens associated with human gliomas", Neurol Res, (19860000), vol. 8, no. 2, pages 123 - 126
    - YATES AJBECKER LESACHS LA, "Brain tumors in childhood", Childs Brain, (19790000), vol. 5, no. 1, pages 31 - 39
    - BERRA BGAINI SMRIBONI L, "Correlation between ganglioside distribution and histological grading of human astrocytomas", Int J Cancer, (19850000), vol. 36, no. 3, pages 363 - 366
    - MANSSON JE et al., "Characterization of new gangliosides of the lactotetraose series in murine xenografts of a human glioma cell line", FEBS Lett, (19860000), vol. 201, no. 1, doi:10.1016/0014-5793(86)80580-4, pages 109 - 113, XP025592230

DOI:   http://dx.doi.org/10.1016/0014-5793(86)80580-4
    - FREDMAN PHOIST HCOLLINS VPDELLHEDEN BSVENNERHOLM L, "Expression of gangliosides GD3 and 3'-isoLMl in autopsy brains from patients with malignant tumors", J Neurochem, (19930000), vol. 60, no. 1, pages 99 - 105
    - KATO Y et al., "GMab-1, a high-affinity anti-3'-isoLMl/3',6'-isoLDl IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice", Biochem Biophys Res Commun, (20100000), vol. 391, no. 1, pages 750 - 755
    - SCHENKEL-BRUNNER H, P System, Human Blood Groups, (19950000), pages 211 - 234
    - KANNAGI R et al., "Stage-specific embryonic antigens (SSEA-3 and -4) are epitopes of a unique globo-series ganglioside isolated from human teratocarcinoma cells", EMBO J, (19830000), vol. 2, no. 12, pages 2355 - 2361, XP008102258
    - ZHANG S et al., "Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides", Int J Cancer, (19970000), vol. 73, no. 1, doi:10.1002/(SICI)1097-0215(19970926)73:1<42::AID-IJC8>3.0.CO;2-1, pages 42 - 49, XP055550796

DOI:   http://dx.doi.org/10.1002/(SICI)1097-0215(19970926)73:1<42::AID-IJC8>3.0.CO;2-1
    - CHANG WW et al., "Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis", Proc Natl Acad Sci U S A, (20080000), vol. 105, no. 33, doi:10.1073/pnas.0804979105, pages 11667 - 11672, XP009124986

DOI:   http://dx.doi.org/10.1073/pnas.0804979105
    - HUANG YL et al., "Carbohydrate-based vaccines with a glycolipid adjuvant for breast cance", Proc Natl Acad Sci USA, (20130000), vol. 110, no. 7, doi:10.1073/pnas.1222649110, pages 2517 - 2522, XP055394157

DOI:   http://dx.doi.org/10.1073/pnas.1222649110
    - SAITO S et al., "xpression of globo-series gangliosides in human renal cell carcinoma", Jpn J Cancer Res, (19970000), vol. 88, no. 7, pages 652 - 659
    - KANNAGI R et al., "New globoseries glycosphingolipids in human teratocarcinoma reactive with the monoclonal antibody directed to a developmentally regulated antigen, stage-specific embryonic antigen 3", J Biol Chem, (19830000), vol. 258, no. 14, pages 8934 - 8942
    - WANG CC et al., "Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer", Proc Natl Acad Sci USA, (20080000), vol. 105, no. 33, pages 11661 - 11666
    - ZAREI MMUTHING JPETER-KATALINIC JBINDILA L, "Separation and identification of GMlb pathway Neu5Ac- and Neu5Gc gangliosides by on-line nanoHPLC-QToF MS and tandem MS: toward glycolipidomics screening of animal cell lines", Glycobiology, (20100000), vol. 20, no. 1, pages 118 - 126
    - GOTTSCHLING S et al., "Stage-specific embryonic antigen-4 is expressed in basaloid lung cancer and associated with poor prognosis", Eur Respir J, (20130000), vol. 41, no. 3, doi:10.1183/09031936.00225711, pages 656 - 663, XP055142330

DOI:   http://dx.doi.org/10.1183/09031936.00225711
    - YE FLI YHU YZHOU CCHEN H, "Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma", Int J Gynecol Cancer, (20100000), vol. 20, no. 6, pages 958 - 964
    - BRIMBLE SN et al., "The cell surface glycosphingolipids SSEA-3 and SSEA-4 are not essential for human ESC pluripotency", Stem Cells, (20070000), vol. 25, no. 1, pages 54 - 62
    - VAN SLAMBROUCK SSTEELANT WF, "Clustering of monosialyl-Gb5 initiates downstream signalling events leading to invasion of MCF-7 breast cancer cells", Biochem J, (20070000), vol. 401, no. 3, doi:10.1042/BJ20060944, pages 689 - 699, XP008140655

DOI:   http://dx.doi.org/10.1042/BJ20060944
    - HUNG TCLIN CWHSU TLWU CYWONG CH, "Investigation of SSEA-4 binding protein in breast cancer cells", JAm Chem Soc, (20130000), vol. 135, no. 16, doi:10.1021/ja312210c, pages 5934 - 5937, XP055218262

DOI:   http://dx.doi.org/10.1021/ja312210c
    - SAITO S et al., "Human alpha2,3-sialyltransferase (ST3Gal II) is a stage-specific embryonic antigen-4 synthase", J Biol Chem, (20030000), vol. 278, no. 29, pages 26474 - 26479
    - KUDO T et al., "Up-regulation of a set of glycosyltransferase genes in human colorectal cancer", Lab Invest, (19980000), vol. 78, no. 7, pages 797 - 811
    - GREEN MR, "Targeting targeted therapy", N Engl J Med, (20040000), vol. 350, no. 21, pages 2191 - 2193
    - MISHIMA K et al., "Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor", Cancer Res, (20010000), vol. 61, no. 14, pages 5349 - 5354
    - WIKSTRAND CJCOKGOR ISAMPSON JHBIGNER DD, "Monoclonal antibody therapy of human gliomas: current status and future approaches", Cancer Metastasis Rev, (19990000), vol. 18, no. 4, pages 451 - 464
    - DURRANT LGNOBLE PSPENDLOVE I, "Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy", Clin Exp Immunol, (20120000), vol. 167, no. 2, pages 206 - 215
    - YU AL et al., "Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma", N Engl J Med, (20100000), vol. 363, no. 14, doi:10.1056/NEJMoa0911123, pages 1324 - 1334, XP055045834

DOI:   http://dx.doi.org/10.1056/NEJMoa0911123
    - LOBUGLIO, A.F.WHEELER, R.H.TRANG, J.HAYNES, A.ROGERS, K.HARVEY, E.B.SUN, L.GHRAYEB, J.KHAZAELI, M.B., "Mouse/human chimeric monoclonal antibody in man: kinetics and immune response", Proc Natl Acad Sci U S A, (19890000), vol. 86, doi:10.1073/pnas.86.11.4220, pages 4220 - 4224, XP002100301

DOI:   http://dx.doi.org/10.1073/pnas.86.11.4220
    - LU, R.-M.CHANG, Y.-L.CHEN, M.-S.WU, H.-C., "Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery", Biomaterials, (20110000), vol. 32, pages 3265 - 3274
    - ROGUSKA, M.A.PEDERSEN, J.T.KEDDY, C.A.HENRY, A.H.SEARLE, S.J.LAMBERT, J.M.GOLDMACHER, V.S.BLATTLER, W.A.REES, A.R.GUILD, B.C., "Humanization of murine monoclonal antibodies through variable domain resurfacing", Proc Natl Acad Sci U S A, (19940000), vol. 91, doi:10.1073/pnas.91.3.969, pages 969 - 973, XP002271704

DOI:   http://dx.doi.org/10.1073/pnas.91.3.969
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.